These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30115106)

  • 1. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis.
    Rice LM; Mantero JC; Stratton EA; Warburton R; Roberts K; Hill N; Simms RW; Domsic R; Farber HW; Layfatis R
    Arthritis Res Ther; 2018 Aug; 20(1):185. PubMed ID: 30115106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
    Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
    Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis.
    Furukawa T; Matsui K; Kitano M; Yokoyama Y; Sekiguchi M; Azuma N; Imai Y; Hirota S; Yamanishi K; Sano H
    Mod Rheumatol; 2019 May; 29(3):476-483. PubMed ID: 29788800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.
    Coursen JC; Tuhy T; Naranjo M; Woods A; Hummers LK; Shah AA; Suresh K; Visovatti SH; Mathai SC; Hassoun PM; Damico RL; Simpson CE
    Am J Physiol Lung Cell Mol Physiol; 2024 Jul; 327(1):L54-L64. PubMed ID: 38651694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.
    Bauer Y; de Bernard S; Hickey P; Ballard K; Cruz J; Cornelisse P; Chadha-Boreham H; Distler O; Rosenberg D; Doelberg M; Roux S; Nayler O; Lawrie A
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?
    Senturk B; Akdeniz B; Yilmaz MB; Ozcan Kahraman B; Acar B; Uslu S; Birlik M
    Clin Rheumatol; 2020 Jan; 39(1):49-56. PubMed ID: 31129792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.
    Sanges S; Rice L; Tu L; Valenzi E; Cracowski JL; Montani D; Mantero JC; Ternynck C; Marot G; Bujor AM; Hachulla E; Launay D; Humbert M; Guignabert C; Lafyatis R
    Ann Rheum Dis; 2023 Mar; 82(3):365-373. PubMed ID: 36600187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts.
    Gladue H; Steen V; Allanore Y; Saggar R; Saggar R; Maranian P; Berrocal VJ; Avouac J; Meune C; Trivedi M; Khanna D
    J Rheumatol; 2013 Oct; 40(10):1706-11. PubMed ID: 23950183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.
    Morrisroe K; Stevens W; Sahhar J; Rabusa C; Nikpour M; Proudman S;
    Arthritis Res Ther; 2017 Mar; 19(1):42. PubMed ID: 28270192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
    Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
    Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension.
    Kylhammar D; Hesselstrand R; Nielsen S; Scheele C; Rådegran G
    Scand J Rheumatol; 2018 Jul; 47(4):319-324. PubMed ID: 29528272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.
    Thakkar V; Stevens W; Prior D; Youssef P; Liew D; Gabbay E; Roddy J; Walker JG; Zochling J; Sahhar J; Nash P; Lester S; Rischmueller M; Proudman SM; Nikpour M
    Arthritis Res Ther; 2013; 15(6):R193. PubMed ID: 24246100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
    Stefanantoni K; Sciarra I; Vasile M; Badagliacca R; Poscia R; Pendolino M; Alessandri C; Vizza CD; Valesini G; Riccieri V
    Reumatismo; 2015 Mar; 66(4):270-6. PubMed ID: 25829187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.
    Thakkar V; Patterson KA; Stevens W; Wilson M; Roddy J; Sahhar J; Proudman S; Hissaria P; Nikpour M
    Clin Rheumatol; 2018 Jun; 37(6):1563-1571. PubMed ID: 29687288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis-associated pulmonary arterial hypertension.
    Chaisson NF; Hassoun PM
    Chest; 2013 Oct; 144(4):1346-1356. PubMed ID: 24081346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.